Form 4: Exelixis Director Mary Beckerle Receives Significant RSU Grant

Exelixis, Inc. Director Mary C. Beckerle was granted 9,812 restricted stock units (RSUs) on May 29, 2025, which will vest in May 2026.

Summary

• Mary C. Beckerle, a Director of Exelixis, Inc. (EXEL), acquired 9,812 shares of common stock on May 29, 2025.
• This acquisition was in the form of a grant of Restricted Stock Units (RSUs) with a transaction price of $0.
• The RSUs were granted pursuant to the Exelixis, Inc. 2017 Equity Incentive Plan.
• Each RSU is the economic equivalent of one share of Exelixis, Inc. common stock.
• The 9,812 RSUs will vest 100% on May 29, 2026, contingent upon Ms. Beckerle's continuous service through that date.
• Following this reported transaction, Ms. Beckerle beneficially owns 40,218 shares, which includes shares that will be issued upon the vesting of RSUs.

Sentiment

Score: 7

Explanation: The grant of Restricted Stock Units (RSUs) to a director is a routine and positive event, aligning the director's interests with long-term shareholder value. It reflects standard corporate governance and compensation practices, indicating stability and continued incentivization of leadership.

Positives

• The grant of 9,812 Restricted Stock Units (RSUs) to a director aligns her interests with those of the company's shareholders, incentivizing long-term performance.
• The transaction demonstrates the company's continued use of its 2017 Equity Incentive Plan to compensate and retain key personnel, which is a standard practice for corporate governance.

Future Outlook

The document does not provide a general future outlook for the company, focusing solely on a specific insider transaction.

Industry Context

This Form 4 filing details a routine equity compensation event for a director, which is a common practice across publicly traded companies, particularly in the biotechnology and pharmaceutical sectors. Such grants are designed to align the interests of board members with long-term shareholder value, reflecting standard corporate governance practices within the industry.

Comparison to Industry Standards

• Equity compensation, such as Restricted Stock Units (RSUs), is a common practice for director remuneration across the biotechnology and pharmaceutical industries, including companies like Amgen, Gilead Sciences, and Biogen, aiming to align director interests with long-term shareholder value.
• The vesting schedule of one year for 100% of the grant is a typical structure for director RSU awards, comparable to practices observed at peer companies, ensuring continued commitment.

Corporate Governance

Related Party Transactions

• Grant of 9,812 Restricted Stock Units (RSUs) to Mary C. Beckerle, a Director of Exelixis, Inc., as part of her compensation package, which constitutes a related party transaction.

Stakeholder Impact

• **Shareholders:** The grant of RSUs to a director aligns their interests with shareholders, as the value of the compensation is directly tied to the company's stock performance. This also represents a potential minor dilution upon vesting, which is typical for equity compensation.
• **Employees:** No direct impact on general employees is indicated, but it reflects the company's overall compensation philosophy for key personnel and board members.

Next Steps

• Vesting of the 9,812 Restricted Stock Units on May 29, 2026, subject to continuous service by Mary C. Beckerle.

Key Dates

Recommendation

Keywords

Exelixis, EXEL, Form 4, SEC filing, Restricted Stock Units, RSU, equity compensation, insider transaction, director compensation, stock grant